查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1916904

资生心气丸市场：以剂型、销售形式、通路、用途及最终用户划分－2026-2032年全球预测

Ji Sheng Shen Qi Pills Market by Dosage Form, Selling Mode, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年，志成新木丸市场规模为 1.104 亿美元，预计到 2026 年将成长至 1.2298 亿美元，年复合成长率为 5.95%，到 2032 年将达到 1.6554 亿美元。

关键市场统计数据
基准年 2025 1.104亿美元
预计年份：2026年 1.2298亿美元
预测年份 2032 1.6554亿美元
复合年增长率 (%) 5.95%

「Shisei Shinkigan」的策略定向是将传统处方的传承与现代分销、监管和消费者健康趋势相结合。

「济生肾气丸」占据了传统中医与现代消费者健康需求交汇的独特市场，代表着一个融合了数百年历史的配方与现代分销、监管和消费模式的品类。该产品吸引了专注于整合医学的临床医生、寻求肾臟保健和气血调理的消费者以及适应数位商业和严格品质标准的供应链利益相关相关人员的注意。要了解该产品，需要关注其植物成分的来源、生产的一致性、安全性监测以及行销管道——如今，其销售管道已从地方药房扩展到全国医院药房和全球电商平台。

重大的产业发展趋势重新定义了资生心气丸在临床和消费领域的产品品质、分销策略和监管合规性。

「资生心气丸」的市场格局正受到一系列变革的重塑，这些变革涵盖了消费行为、监管预期以及不断演变的通路。消费者日益要求产品具备产地资讯、成分标准化以及第三方安全检验，促使生产商加强对批次检测、供应商审核和更清晰标籤的投入。同时，多个司法管辖区的监管机构正在提高草药产品的监管标准，强调污染物控制、成分标籤的准确性以及能够捕捉植物来源疗法不利事件讯号的强化药物监测系统。

2025年关税调整和海关检查力度加大对依赖进口草药产品的采购计算、供应链韧性和商业性定价策略的影响

美国于2025年实施的贸易政策调整和关税措施，进一步增加了草药製剂及其成分跨境分销的复杂性。虽然这些关税针对的是特定的原料和包装，而非成品，但其累积效应却波及到最终成本、供应商选择和策略采购等各个面向。依赖国际植物原料供应商的製造商面临抉择：要么自行承担额外关税，要么将成本转嫁给经销商，要么将部分价值链转移到其他地区。每种选择都涉及不同的前置作业时间、资本投入和营运风险。

深度細項分析揭示了分销管道、剂型、治疗定位、商业性准入和终端用户趋势如何决定策略重点。

细分市场分析揭示了分销管道、配方、治疗定位、商业性准入以及终端用户群体特征如何共同影响资生心气丸的需求模式和营运重点。从通路（包括医院药局、线上零售（含官网、公司自有行动应用和第三方电商平台）以及零售药局）的角度来看，相关人员必须调整库存时间、促销方式和合规文件，以适应各通路的采购週期和信任讯号。医院药局负责人重视临床证据和供应商信誉，零售药局优先考虑货架即用的包装和麵向消费者的标籤，而线上零售商则要求强大的数位化认证和可靠的配送保障。

影响市场进入、文化接受度和分销策略的区域趋势和监管环境在美洲、欧洲、中东和非洲以及亚太地区各不相同。

「解肾丸」的区域市场趋势反映了不同的管理体制、对传统配方的文化接受度以及分销基础设施，所有这些因素都影响着商业性重点和打入市场策略。在美洲，整合医学专业人士和寻求肾臟保健产品的消费者对「解肾丸」的认知度正在不断提高，但市场准入需要严格的品质文件、进口合规性以及符合当地监管标准的清晰标籤。该地区的分销主要由能够证明分销链控制和安全测试的认证供应商和零售合作伙伴主导，而线上管道则拓展了其在海外韩国人和专业医疗群体中的覆盖范围。

竞争格局概述：製造技术诀窍、证据创造和通路专业化如何创造差异化和韧性

「中药材」领域的竞争格局呈现出多元化的特点，既有传统中药生产商，也有专业的代工生产商、垂直整合的出口商，以及利用D2C通路的数位化原生品牌。现有企业拥有许多优势，例如植物原料采购网络、符合GMP标准的生产设施以及多年积累的监管文件，而新参与企业则透过临床证据、创新剂型和注重可追溯性的高端品牌建设来脱颖而出。契约製造生产商能够为希望外包生产并保持市场灵活性的品牌提供扩充性，但必须证明其具备处理植物原料和控制交叉污染的能力。

为製造商和经销商提供切实有效的策略措施，以提高可追溯性、通路相容性和合应对力，同时保护利润率。

产业领导者应优先考虑兼顾产品完整性、商业性扩充性和监管前瞻性的实际措施。首先，投资建造端到端的可追溯性系统，记录植物成分的来源、批次检测和供应商审核，以满足进口商、机构买家和精通数位技术的消费者的需求。强大的可追溯性能够减少海关和第三方检验的阻力，同时提升品牌信誉。其次，针对每个分销管道优化市场推广策略。为医院药房开发临床文件和官方包装，并为零售药房优化面向患者的标籤和零售即用型SKU。为官方网站、行动应用程式和第三方电子商务平台建立数位认证、安全交付和客户支援机制。

采用严谨的混合方法研究途径，整合相关人员访谈、监管分析和供应链诊断，以获得可操作的见解。

本研究整合了关键相关人员访谈、二手文献综述和供应链诊断，以全面了解再生新气丸生态系统。主要数据透过与生产商、合约药房、经销商、医院药房采购负责人、零售品类经理和数位通路营运商的结构化访谈收集，以了解营运实践和通路特定要求。二级资讯来源，包括监管指导文件、关于植物药和安全性的学术文献、进出口程序手册和公共不利事件报告资料库，用于验证安全性和监管方面的相关主题。

策略重点综合分析表明，品质、证据和管道差异化如何确保机构认可和消费者长期信任。

总之，资生心气丸正处于一个战略十字路口，传统处方原则与日益增长的品质、透明度和合规性要求在此交汇。要获得更广泛的机构认可和永续的消费者成长，关键在于将传统价值提案与现代生产实践、可追溯性体系和基于证据的沟通相结合。积极关注采购流程完整性、分销管道特定要求和监管文件合规性的相关人员，将更有能力应对关税波动、海关检查和不断变化的消费者期望等挑战。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 止痛药丸市场按剂型划分

  • 胶囊
  • 颗粒
  • 药片
  • 药片

第九章：新木丸茂夫市场依销售类型划分

  • 非处方药
  • 处方笺

第十章：新木丸茂夫按分销管道分類的市场

  • 医院药房
  • 线上零售
    • 官方网站
    • 专用行动应用
    • 第三方电子商务平台
  • 零售药房

第十一章 新木丸茂夫 按应用分類的市场

  • 一般健康维护
  • 肾臟健康
  • 气虚

第十二章：新木丸茂夫的最终用户市场

  • 成人版
  • 对于老年人
  • 儿童

第十三章：新木丸茂夫的区域市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 新木丸茂夫市集：依集团划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 新木丸茂夫 各国市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国重雄神奇丸市场

第十七章：中国的五味参丸市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Beijing Tongrentang Co., Ltd.
  • China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
  • Guangzhou Pharmaceutical Holdings Limited
  • Guizhou Qilin Pharmaceutical Co., Ltd.
  • Harbin Pharmaceutical Group Co., Ltd.
  • Jilin Aodong Pharmaceutical Group Co., Ltd.
  • Shijiazhuang Yiling Pharmaceutical Co., Ltd.
  • Tasly Pharmaceutical Group Co., Ltd.
  • Tianjin Zhongxin Pharmaceutical Group Corporation Limited
  • Yunnan Baiyao Group Co., Ltd.
Product Code: MRR-AE420CB153E4

The Ji Sheng Shen Qi Pills Market was valued at USD 110.40 million in 2025 and is projected to grow to USD 122.98 million in 2026, with a CAGR of 5.95%, reaching USD 165.54 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 110.40 million
Estimated Year [2026] USD 122.98 million
Forecast Year [2032] USD 165.54 million
CAGR (%) 5.95%

A strategic orientation to Ji Sheng Shen Qi Pills that connects traditional formulation heritage with contemporary distribution, regulation, and consumer health dynamics

Ji Sheng Shen Qi Pills occupy a distinctive niche at the intersection of traditional herbal practice and modern consumer health demand, representing a category where centuries-old formulations meet contemporary distribution, regulation, and consumption patterns. The product has drawn interest from clinicians focused on integrative care, consumers seeking kidney-support and qi-balancing remedies, and supply chain actors adapting to digital commerce and stricter quality standards. Understanding this product requires attention to botanical sourcing, manufacturing consistency, safety monitoring, and market channels that now extend beyond local apothecaries to national hospital pharmacies and global e-commerce platforms.

This introduction establishes the analytical frame for the report: physiological indications rooted in traditional medical paradigms, the modern implications for clinical and consumer adoption, and the operational challenges manufacturers and distributors face in ensuring quality, traceability, and regulatory compliance. The narrative that follows situates Ji Sheng Shen Qi Pills within shifting consumer health priorities, evolving regulatory scrutiny, and a distribution landscape that accommodates hospital pharmacy procurement, retail pharmacy stocking decisions, and an expanding suite of online retail touchpoints. By connecting formulation heritage with contemporary supply chain dynamics, readers will gain a practical orientation for interpreting subsequent sections on trade policy, segmentation, regional considerations, competitive dynamics, and actionable recommendations.

Critical industry forces redefining product integrity, channel strategy, and regulatory compliance for Ji Sheng Shen Qi Pills across clinical and consumer landscapes

The landscape for Ji Sheng Shen Qi Pills is being reshaped by a constellation of transformative shifts spanning consumer behavior, regulatory expectations, and channel evolution. Consumers are increasingly seeking products that demonstrate provenance, standardized composition, and third-party safety verifications, prompting manufacturers to invest in batch testing, supplier audits, and clearer labeling. Simultaneously, regulators in multiple jurisdictions have raised the bar for herbal products, emphasizing contaminant control, accurate ingredient declaration, and pharmacovigilance systems that can capture adverse-event signals for botanically derived therapies.

Channel dynamics are evolving in parallel. Traditional retail pharmacy networks continue to serve as a credibility gateway, while hospital pharmacy procurement is becoming more receptive to integrative therapies when supported by clinical evidence or formulary-level endorsements. Online retail is accelerating reach but also heightening the need for digital authenticity measures, controlled distribution of prescription-containing SKUs, and post-market customer support. Taken together, these trends demand that stakeholders balance heritage-driven product narratives with modern quality assurance, cross-channel consistency, and regulatory alignment to sustain both consumer trust and institutional acceptance.

How 2025 tariff shifts and heightened customs scrutiny have altered sourcing calculus, supply chain resilience, and commercial pricing strategies for import-dependent herbal products

Trade policy shifts and tariff measures enacted by the United States in 2025 have introduced additional layers of complexity to the cross-border movement of herbal formulations and their constituent raw materials. Even when tariffs target specific inputs or packaging elements rather than finished goods, the cumulative effect reverberates across landed costs, supplier selection, and strategic sourcing. Manufacturers that rely on international botanical suppliers have confronted choices between absorbing incremental duties, passing costs to distributors, or relocating portions of the value chain to alternative jurisdictions. Each pathway implies different lead times, capital expenditures, and operational risk profiles.

Indirect consequences have also emerged. Heightened tariffs and customs scrutiny can slow port throughput and increase documentary requirements, which in turn amplify working capital needs for inventory and expose perishable botanical inputs to quality deterioration risks. Regulatory documentation and certification burdens have intensified as importers seek to expedite customs clearance; firms investing in robust traceability and compliance documentation have experienced relatively smoother cross-border flows. The tariff environment has therefore incentivized players to diversify manufacturing footprints, strengthen supplier qualification programs, and explore nearshoring options where feasible, while trade-exposed distributors have reassessed pricing strategies and contractual terms to sustain margins and market access.

Deep segmentation analysis revealing how distribution channels, dosage formats, therapeutic positioning, commercial access, and end-user dynamics define strategic priorities

Segmentation insights reveal how distribution, formulation, therapeutic positioning, commercial access, and end-user demographics each shape demand patterns and operational priorities for Ji Sheng Shen Qi Pills. When viewed through distribution channel lenses such as hospital pharmacy, online retail-including official websites, proprietary mobile apps, and third-party e-commerce platforms-and retail pharmacy, stakeholders must calibrate inventory cadence, promotional approaches, and compliance documentation to match each channel's procurement cycles and trust signals. Hospital pharmacy buyers emphasize clinical evidence and supplier reliability, retail pharmacies prioritize shelf-ready packaging and consumer-facing claims, and online retail demands robust digital verification and fulfillment reliability.

Dosage form distinctions across capsules, granules, pills, and tablets materially influence manufacturing complexity, scalability, and consumer preference. Capsules and tablets offer dosing precision and shelf stability conducive to broader retail distribution, while granules appeal to consumers favoring traditional preparation methods and may require different storage and labelling approaches. Application segmentation across general wellness, kidney health, and qi deficiency drives messaging nuance: wellness positioning broadens appeal, kidney-focused claims raise the bar for clinical substantiation, and qi deficiency narratives often necessitate culturally contextual communication. Selling mode-over the counter versus prescription-affects channel eligibility, claims architecture, and regulatory reporting. End-user segmentation including adult, geriatric, and pediatric cohorts further informs formulation decisions, dosing guidance, and safety monitoring approaches, because each demographic group presents distinct pharmacological sensitivities, adherence behaviors, and caregiver involvement that must be addressed in product development and commercial plans.

Regional dynamics and regulatory contours that determine market access, cultural receptivity, and distribution strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics for Ji Sheng Shen Qi Pills reflect differing regulatory regimes, cultural acceptance of traditional formulations, and distribution infrastructure, all of which shape commercial priorities and go-to-market design. In the Americas, acceptance has been growing among integrative medicine practitioners and consumer segments seeking complementary kidney-support products, but market access is contingent on rigorous quality documentation, import compliance, and clear labeling that meets local regulatory standards. Distribution in this region often favors certified suppliers and retail partners who can demonstrate chain-of-custody and safety testing, while online channels have expanded reach among diaspora and specialty wellness communities.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory convergence varies across subregions and national frameworks. In parts of Europe, strict novel foods and herbal product rules require careful dossier preparation and sometimes localized clinical evidence, which influences market entry sequencing. Middle Eastern markets may show strong consumer interest where cultural familiarity with botanical remedies exists, yet import rules and halal-compliant documentation can be decisive. African markets offer both opportunity and complexity, with supply chain constraints and local regulatory capacity shaping partner selection. In the Asia-Pacific, cultural familiarity with traditional herbal medicines and established distribution networks in several countries enable broader consumer acceptance, but regional harmonization efforts and increased scrutiny of contaminants and heavy metals necessitate elevated quality controls and supplier transparency to support institutional adoption and cross-border trade.

Competitive landscape overview highlighting how manufacturing expertise, evidence generation, and channel specialization create differentiation and resilience

Competitive dynamics in the Ji Sheng Shen Qi Pills category are characterized by a mix of legacy herbal manufacturers, specialized contract formulators, vertically integrated exporters, and digitally native brands that leverage direct-to-consumer channels. Established manufacturers often possess advantages in botanical sourcing networks, GMP-capable facilities, and long-standing regulatory dossiers, while newer entrants differentiate through clinical evidence generation, novel dosage formats, or premium branding focused on traceability. Contract manufacturing organizations provide scalability for brands seeking to outsource production while retaining marketing agility, but they must demonstrate capability in botanical handling and cross-contamination controls.

Partnerships between clinical research groups and product developers have contributed to a rise in evidence-focused propositions, and distributors with robust cold chain and regulatory affairs teams have gained preferred status among institutional buyers. Digital platforms and third-party e-commerce marketplaces have lowered barriers to consumer access but require brands to prioritize anti-counterfeit measures, authenticated product listings, and post-sale support. Overall, companies that combine stringent quality systems, transparent supply chains, and channel-specific go-to-market capabilities are best positioned to navigate regulatory scrutiny and capture institutional and consumer trust.

Practical, high-impact strategic moves for manufacturers and distributors to strengthen traceability, channel fit, and regulatory readiness while protecting margins

Industry leaders should prioritize a set of actionable moves that align product integrity with commercial scalability and regulatory foresight. First, invest in end-to-end traceability systems that document botanical origin, batch testing, and supplier audits to satisfy importers, institutional buyers, and digitally savvy consumers. Robust traceability reduces the friction of customs and third-party verification while enhancing brand credibility. Second, tailor go-to-market strategies by channel: develop clinical dossiers and formal packaging for hospital pharmacy procurement, optimize patient-facing labeling and retail-ready SKUs for retail pharmacy, and implement digital authentication, fulfillment reliability, and customer support protocols for official websites, mobile apps, and third-party e-commerce platforms.

Third, diversify manufacturing and sourcing footprints where feasible to mitigate tariff exposure, port congestion, and single-supplier risk; nearshoring or dual-sourcing strategies can shorten lead times and improve quality oversight. Fourth, develop a pragmatic evidence roadmap that aligns claims with regulatory thresholds: invest in targeted clinical or real-world studies that support kidney-health and qi-related claims while ensuring adverse-event monitoring mechanisms are in place. Finally, strengthen commercial contracts and pricing frameworks to reflect increased supply-chain costs and compliance requirements, ensuring that distributor agreements and channel incentives preserve margin while maintaining affordability for key end-user segments like geriatric and pediatric populations.

Rigorous, mixed-method research approach integrating stakeholder interviews, regulatory analysis, and supply-chain diagnostics to derive actionable intelligence

This research synthesizes primary stakeholder interviews, secondary literature review, and supply-chain diagnostics to produce a balanced view of the Ji Sheng Shen Qi Pills ecosystem. Primary data were collected through structured discussions with manufacturers, contract formulators, distributors, hospital pharmacy procurement officers, retail category managers, and digital channel operators to capture operational realities and channel-specific requirements. Secondary sources included regulatory guidance documents, academic literature on botanicals and safety considerations, import/export procedural manuals, and public adverse-event reporting databases to triangulate safety and regulatory themes.

Analytical methods included comparative channel analysis to identify procurement and fulfillment differentials, supplier risk matrices to evaluate sourcing vulnerabilities, and scenario mapping to assess trade-policy impacts on lead times and landed compliance obligations. Quality assurance was assured through cross-validation of primary interview findings with documentary evidence from regulatory and industry standards. Throughout, emphasis was placed on actionable intelligence-linking operational levers such as manufacturing controls, documentation practices, and channel-specific packaging to observable outcomes in distribution, institutional acceptance, and consumer confidence.

A synthesis of strategic priorities showing how quality, evidence, and channel differentiation secure institutional acceptance and long-term consumer trust

In conclusion, Ji Sheng Shen Qi Pills sit at a strategic junction where heritage formulation principles meet heightened expectations for quality, transparency, and regulatory conformity. The path to broader institutional acceptance and sustainable consumer growth lies in harmonizing traditional value propositions with modern manufacturing practices, traceability systems, and evidence-aligned communication. Stakeholders that proactively address sourcing integrity, channel-specific requirements, and regulatory documentation will be better positioned to navigate tariff disruptions, customs scrutiny, and evolving consumer expectations.

Moving forward, the most resilient strategies blend operational investments-such as enhanced supplier qualification, diversified manufacturing footprints, and targeted clinical or real-world studies-with commercial adaptations tailored to hospital pharmacy, retail pharmacy, and online retail contexts. By aligning product stewardship with channel sophistication and regulatory preparedness, organizations can preserve the therapeutic heritage of Ji Sheng Shen Qi Pills while meeting the demands of contemporary health ecosystems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Ji Sheng Shen Qi Pills Market, by Dosage Form

  • 8.1. Capsules
  • 8.2. Granules
  • 8.3. Pills
  • 8.4. Tablets

9. Ji Sheng Shen Qi Pills Market, by Selling Mode

  • 9.1. Over The Counter
  • 9.2. Prescription

10. Ji Sheng Shen Qi Pills Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Retail
    • 10.2.1. Official Website
    • 10.2.2. Proprietary Mobile App
    • 10.2.3. Third-Party E-Commerce Platform
  • 10.3. Retail Pharmacy

11. Ji Sheng Shen Qi Pills Market, by Application

  • 11.1. General Wellness
  • 11.2. Kidney Health
  • 11.3. Qi Deficiency

12. Ji Sheng Shen Qi Pills Market, by End User

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Ji Sheng Shen Qi Pills Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Ji Sheng Shen Qi Pills Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Ji Sheng Shen Qi Pills Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Ji Sheng Shen Qi Pills Market

17. China Ji Sheng Shen Qi Pills Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Beijing Tongrentang Co., Ltd.
  • 18.6. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
  • 18.7. Guangzhou Pharmaceutical Holdings Limited
  • 18.8. Guizhou Qilin Pharmaceutical Co., Ltd.
  • 18.9. Harbin Pharmaceutical Group Co., Ltd.
  • 18.10. Jilin Aodong Pharmaceutical Group Co., Ltd.
  • 18.11. Shijiazhuang Yiling Pharmaceutical Co., Ltd.
  • 18.12. Tasly Pharmaceutical Group Co., Ltd.
  • 18.13. Tianjin Zhongxin Pharmaceutical Group Corporation Limited
  • 18.14. Yunnan Baiyao Group Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL JI SHENG SHEN QI PILLS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL JI SHENG SHEN QI PILLS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES JI SHENG SHEN QI PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA JI SHENG SHEN QI PILLS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GRANULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GRANULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GRANULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY OFFICIAL WEBSITE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY OFFICIAL WEBSITE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY OFFICIAL WEBSITE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PROPRIETARY MOBILE APP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PROPRIETARY MOBILE APP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PROPRIETARY MOBILE APP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY THIRD-PARTY E-COMMERCE PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY THIRD-PARTY E-COMMERCE PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY THIRD-PARTY E-COMMERCE PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GENERAL WELLNESS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GENERAL WELLNESS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GENERAL WELLNESS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY KIDNEY HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY KIDNEY HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY KIDNEY HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY QI DEFICIENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY QI DEFICIENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY QI DEFICIENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS JI SHENG SHEN QI PILLS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. GCC JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 129. GCC JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 130. GCC JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GCC JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 132. GCC JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. GCC JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. G7 JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 150. G7 JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 151. G7 JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. G7 JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 153. G7 JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. G7 JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NATO JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 157. NATO JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 158. NATO JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. NATO JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 160. NATO JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. NATO JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL JI SHENG SHEN QI PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES JI SHENG SHEN QI PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA JI SHENG SHEN QI PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA JI SHENG SHEN QI PILLS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA JI SHENG SHEN QI PILLS MARKET SIZE, BY SELLING MODE, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA JI SHENG SHEN QI PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA JI SHENG SHEN QI PILLS MARKET SIZE, BY ONLINE RETAIL, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA JI SHENG SHEN QI PILLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA JI SHENG SHEN QI PILLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)